Neurocrine Biosciences, Inc. (NBIX) Earnings Call Transcript
February 11, 2026
Earnings Call Speaker Segments
Good Wednesday, everyone, and thank you for joining Neurocrine Biosciences' call covering the fourth quarter and year-end 2025 results. Joining me on the line today are Kyle Gano, our Chief Executive Officer; Matt Abernethy, Chief Financial Officer; Eric Benevich, Chief Commercial Officer; and Sanjay Keswani, Chief Medical Officer. We are also delighted to have Samir Siddhanti, Vice President of Strategy and Corporate Development, with us for the first time. On this call, we will make forward-looking statements, which carry certain risks and uncertainties, and actual results could differ materially. We encourage you to review the risk factors described in our most recent SEC filings. Following the prepared remarks, we will be glad to take your questions. With that, I'll hand things over to Kyle.
Thanks, Todd, and good afternoon, everyone. One clear sign of a healthy company is how solid its foundation is. As Neurocrine moves into 2026, that foundation is stronger than at any other moment in our history of more than 30 years, and it keeps getting stronger; with momentum building across the whole enterprise and with strategic, balanced diversification, Neurocrine has entered a new era of meaningful growth driven by our first and best-in-class commercial brands. INGREZZA keeps delivering impressive results. Strategic investments in access and in expanding our sales force produced a record year for both new and total prescriptions. That momentum carries into 2026, where, even nine years after launch, we anticipate double-digit volume-driven growth, supported by ongoing demand from the roughly nine out of 10 TD or HD chorea patients who are not currently taking a VMAT2 inhibitor. Like INGREZZA, the launch of CRENESSITY has also been exceptionally strong. By the close of the fourth quarter, our first full commercial year following its approval in December 2024, prescriptions had reached over 10% of the classic congenital adrenal hyperplasia patient population, which underscores the tremendous unmet need. What a great start, and I want to thank our team for making all of this possible. This strong early adoption among patients, caregivers, and prescribers reinforces our conviction that CRENESSITY will become Neurocrine's second blockbuster product; with an FDA-approved label supporting uncompromised efficacy, including an efficacious first dose with no titration requirement, multiple formulations for pediatric and adult populations, and a favorable safety and tolerability profile, CRENESSITY is quickly becoming the standard of care for patients with classic CAH; this profile mirrors the attributes that supported INGREZZA's success and underscores our confidence in CRENESSITY's impact for patients and for Neurocrine going forward. Turning to research and development, at our December R&D Day, we laid out three strategic pillars. First, we intend to lead the VMAT2 category by drawing on our deep INGREZZA experience to advance next-generation VMAT2 inhibitors. As background, INGREZZA was the first approved treatment for tardive dyskinesia, and Neurocrine paved the way for developing new medicines in this space. Our history of nearly 20 years provides a durable foundation for category leadership. This begins with NBI-890, which recently entered phase II in tardive dyskinesia, and with NBI-675, which is following close behind. Both of these products have potential for long-acting injectable formulations. Second, we are delivering on the promise of CRF through a two-pronged approach, advancing next-generation CRF1 antagonists such as NBI-1435 for CAH, and expanding the platform with CRF2 agonists starting with NBI-2118 into adjacent areas, including metabolic diseases such as obesity; for more than 30 years, Neurocrine has been a pioneer in CRF biology, and this experience uniquely positions us to evolve and expand what CRF-based therapies can deliver. Third, we are maximizing and evolving the pipeline, which is stronger than ever. This is led by our late-stage, industry-leading neuropsychiatry portfolio, including two phase III programs: osavampator in major depressive disorder and direlotide in schizophrenia. Just as with INGREZZA and CRENESSITY, each of these candidates could become a first-in-class and best-in-class therapy. Top-line results are anticipated in 2027 from the osavampator trials and from the first of the two direlotide trials, and that year looks set to bring more data than any other in Neurocrine's history. During 2025, we met our phase I through phase III goals for the very first time, which made it the most productive clinical year the company has ever had. We can also see a clear path to matching that level of performance in 2026, which moves us faster toward our aim of bringing out one new medicine every two years at steady state. As I noted at the beginning, we head into 2026 with the strongest foundation Neurocrine has ever had. It falls to me, to our leadership team, and to the whole organization to keep executing and delivering on behalf of patients and shareholders. We thank you for your support, and with that, I'll hand the call over to Matt.
Thank you, Kyle, and good afternoon to all of you. For Neurocrine, 2025 stood out as a remarkable year. Total product sales climbed past $2.8 billion, which works out to 22% growth compared with the prior year; that result speaks to the sustained strength and durability of INGREZZA along with a successful first launch for CRENESSITY. These two products serve as the basis for our growth and produce durable cash flows that underpin long-term value creation for shareholders. INGREZZA brought in slightly above $2.5 billion in revenue, an increase of 9% year-over-year, powered by volume growth in the double digits, partly offset by pricing concessions tied to formulary access investments meant to support long-term growth. Fourth quarter results came in as expected based on what we laid out on our Q3 call. New prescriptions are still close to the record levels we hit in Q3, which is a strong outcome considering the sales force expansion that is underway. Going forward, our guidance for INGREZZA sales in 2026 falls between $2.7 billion and $2.8 billion, which implies roughly 10% growth; that outlook captures continued double-digit volume growth, including contributions from the expanded sales force during the second half of the year, partly offset by price declines connected to formulary access improvements put in place during 2025. On the whole, we anticipate net pricing in 2026 will be fairly consistent with the levels we saw exiting 2025. INGREZZA heads into the year with solid NRX momentum, broad access, and a larger commercial team prepared to execute. On CRENESSITY, we closed out 2025 with more than $300 million in net product sales and about 10% of addressable patients receiving prescriptions for CRENESSITY. Because this is a first-in-disease launch, enrollment form activity can fluctuate from quarter to quarter, but our confidence comes from the number of patients on therapy, refill behavior, and how quickly reimbursement moves. Feedback continues to be extremely positive, and our first year on the market beat both internal and external expectations. Since CRENESSITY is the first product approved for classic CAH in over 70 years, and there is still much to learn about market dynamics, we are not offering specific sales guidance for 2026. Eric will later discuss on the call the initiatives underway to keep developing this attractive market. Shifting to the financials, our cash position rose by roughly $700 million, from $1.8 billion at the close of 2024 to $2.5 billion at the close of 2025, which reflects strong operating performance and a healthy balance sheet. Although maximizing near-term profitability is not our main objective, we stay highly profitable, posting approximately 30% non-GAAP operating margin, or about $850 million of non-GAAP operating income for 2025, including $83 million of R&D milestones and IP R&D expense; for 2026, we anticipate another strong year of non-GAAP operating income, driven by higher product sales and partly offset by investments across SG&A and R&D. These investments line up with our top capital allocation priorities: driving revenue growth and advancing our pipeline. The year-over-year SG&A increase mainly reflects investments tied to our 2026 sales force expansion, which we expect to wrap up by the end of the first quarter. At the midpoint of our guidance range, GAAP SG&A for 2026 is expected to land in the low 40% of sales. Growth in R&D spending comes from a full year of funding our phase III programs for osavampator and direlotide, which should generate data in 2027, along with launching several phase II and phase I efforts, obesity among them. On the whole, we anticipate GAAP R&D expense—leaving out roughly $25 million of milestones—landing in the mid-30% of sales range, in line with what we said previously. All told, 2026 looks like it will be another significant year for Neurocrine as we keep growing INGREZZA and CRENESSITY and push our pipeline forward. We head into the year carrying strong momentum and are well-positioned for continued growth. With that, I'll hand the call to Eric Benevich, our Chief Commercial Officer. Eric.
Thanks, Matt. I feel a great deal of pride in what our team accomplished last year with both CRENESSITY and INGREZZA, and I'm just as excited about the substantial opportunity that lies ahead for these two brands. Since Matt already went through the financial highlights, what I'll do is offer some added perspective and point out the main areas of focus that will fuel continued growth for both products. On the CRENESSITY launch, you've heard our phrase, "So far, so great." And 2025 truly delivered on that promise, generating more than $300 million in net sales during its first full year on the market. Across 2025, demand was strong among pediatric and adult patients alike and across both genders, and prescriptions are now moving toward a majority being pediatric patients and female patients on therapy. Importantly, even though new patient starts can fluctuate week to week and quarter to quarter, patients who begin treatment with CRENESSITY generally remain on CRENESSITY. What we're seeing in the real world matches what we observed in the open-label extension studies. As we've stated from the beginning, CRENESSITY, being a first-in-disease medicine, is a learning launch, much like what we experienced with INGREZZA in TD; in fact, the similarities between these two launches are strikingly close. Both INGREZZA and CRENESSITY address diseases that lacked any FDA-approved therapy designed specifically for them—they're first-in-disease treatments—and in their initial twelve months on the market, each generated sales of roughly $300 million. Since these launches are the first of their kind for the diseases in question, we still have much to discover about who the patients are, which physicians prescribe the drugs, and whether seasonal patterns may emerge. Just as was true with INGREZZA, we are not providing specific annual guidance for year two, yet our confidence remains very high that CRENESSITY will turn into Neurocrine's second blockbuster product as we work to establish it—together with replacement glucocorticoids—as the standard of care for classic congenital adrenal hyperplasia patients. Now that we're entering CRENESSITY's second full year on the market, the obvious question is, "So what's next?" As I mentioned this time last year, long-term success for CRENESSITY will depend on how well we reach, educate, and activate the CAH community around this breakthrough medicine. To date, over 1,000 prescribers have written a prescription for CRENESSITY, but roughly 2/3 have treated only one patient so far, which highlights both the progress we've made and the opportunity that remains. To support continued growth, we're concentrating on several key priorities in 2026. We already told you we're expanding the CRENESSITY sales team, and new reps will be out in the field in April. Since this is a rare disease team, total FTE counts stay modest. Still, this growth lets us reach further into the endocrinology HCP base we already have and connect with more possible prescribers. Endocrinologists are still at the center, but we've found that primary care providers or OB/GYNs handle some classic CAH patients outside of endocrinology. We're keen to use AI and other tech tools to help spot and engage providers who are likely treating classic CAH patients. We also keep putting money into medical education so the community better understands CAH, the limits of GC monotherapy, and has CRENESSITY's compelling product profile reinforced. It is still the first and only new treatment specific to CAH in 70 years. A potent and selective CRF1 antagonist, CRENESSITY goes after the source of dysregulation in CAH and directly blocks the surge of excess ACTH from the pituitary, restoring downstream androgen control and making physiologic steroid dosing possible. Beyond that, CRENESSITY holds the biggest collection of data covering both adults and children with classic CAH—over 450 patient years from clinical trials plus upwards of 550 patient years gathered in real-world settings. With a long-term safety picture that looks good, strong efficacy, and wide labeling, it's easy to see why adoption has been so vigorous only a year after launch. As a matter of fact, our estimate is that we've managed to treat approximately 10% of the classic CAH population during the first year it was available. For us, that represents a significant milestone. Our expectation is that continued peer-to-peer influence—fueled by growing awareness within the CAH community, an expanding endocrinology prescriber base, and clinicians sharing real-world clinical experience—will deepen understanding of the disease and support wider adoption. Shifting to INGREZZA, 2025 brought both a record count of new patient starts and a record count of patients overall on therapy. As of today, we estimate that just roughly 10% of the prevalent TD population is presently on a VMAT2 inhibitor. Nine years after launch, we still see a big chance to expand the class, increase our share of the market, and assist additional patients in beginning and continuing treatment; given double-digit growth momentum, solid formulary access, a sales force that has been expanded and reorganized and is scheduled to enter the field in Q2, a differentiated product profile that leads its class, and another 12 years of exclusivity remaining, INGREZZA is well-positioned to help a great many more TD and HD patients; so with that, I'll hand the call to my colleague, Dr. Sanjay Keswani, who will discuss our pipeline progress.
Thanks, Eric, and good afternoon everyone. In line with this year's focus on momentum and strategic diversification, our clinical team will be enrolling and advancing a greater number of studies than at any other point in Neurocrine's history. While most of what I say about earnings going forward will center on enrollment progress and trial launches, I'd like to use today to highlight recently disclosed data on our two commercial products, INGREZZA and CRENESSITY. Head-to-head trials are one of the best ways to compare therapies. With that in mind, we recently presented first-of-its-kind head-to-head data comparing INGREZZA with Austedo XR at the 64th annual meeting of the American College of Neuropharmacology. PET imaging findings confirmed our long-held view: VMAT2 inhibitors are not all alike. In this study, INGREZZA demonstrated VMAT2 target occupancy close to twice as high as therapeutic doses of Austedo XR — a key finding showing that INGREZZA delivers superior efficacy when treating tardive dyskinesia. Turning to CRENESSITY, we recently shared data from our open-label extension study. Several analyses remain in progress and will be presented at forthcoming endocrinology meetings, ENDO 2026 among them, yet the core message is evident: in both adult and pediatric CAH patients, CRENESSITY keeps delivering strong, sustained, clinically meaningful benefits throughout two years of treatment. We observe lasting decreases in excess ACTH and androgens, tackling the underlying pathophysiology of CAH directly while preserving control over time. For pediatric patients, CRENESSITY maintained consistent ACTH suppression while keeping normal physiological signaling intact, including the immune response to stress. Consequently, adrenal insufficiency occurred at very low rates: none in the pediatric double-blind trial and 1.6% among adults, with no difference between those on active treatment and those on placebo. We also saw, in a prepubertal subgroup, that bone age advancement slowed, which translates into a predicted adult height gain exceeding two inches. Among adults, roughly 70% of patients reached the physiological steroid range while androgen control was maintained, and approximately 40% of overweight or obese patients lost at least 5% of their weight across two years, which reflects the beneficial cardiometabolic effects of CRENESSITY. Safety and tolerability continued to look very good. At the two-year mark, retention was roughly 80%, we saw no new safety signals, and exposure totaled more than 35,000 patient weeks. Taken together, these results strengthen the case that CRENESSITY is strongly differentiated on efficacy, safety, and tolerability, and they back our belief that it will remain the standard of care for patients with classical congenital adrenal hyperplasia. Turning to our neuropsychiatry programs, which lead the industry: the late-stage phase III trials of osavampator in major depressive disorder and of direlotide in schizophrenia are enrolling at a good pace, and only last month we began a phase II study of NBI-890, our next-generation VMAT2 inhibitor being developed to treat tardive dyskinesia. Every remaining study in our pipeline is progressing according to plan, and we're eager to keep you updated on how things develop. Kyle, I'll now return the call to you.
Thanks, Sanjay. I think we can go ahead and take questions now.
Hi there, good afternoon. Congratulations, and thank you for taking my question. I appreciate that no guidance is being given on CRENESSITY, but I was wondering whether you might offer us either some visibility into the first six weeks of 2026 or, more broadly, just the figure on the revenue side — obviously far above consensus in 4Q — but when we look at start forms, there's a modest drop from 2Q to 3Q and from 3Q to 4Q. I'm curious about your perspective on what you're seeing right now and where you think this kind of patient ad rate might plateau in, say, the near to midterm. Thank you.
Paul, so we're going to begin putting weekly sales information out on the web. Just kidding. I mean, it's been a tremendous year for.
Love it.
CRENESSITY has had a tremendous year — more than $300 million in year one. Congrats to the team; we're really looking forward to year two being another strong and exciting one. We do expect meaningful, steady additions of new patients each and every quarter. That should make for a very nice growth year. Of course, we still have a great deal to learn with this launch. As you recall, with INGREZZA it took roughly four years before we got to a guide, but we'll be giving insight every quarter when it comes to net sales, demand, and the overall reimbursement dynamics. Looking around the table, I'd say we couldn't be prouder of the team and what's been achieved this year, and we truly feel good about how we're positioned for the years ahead.
I'm looking forward to those weekly updates.
Hi there, good afternoon. Appreciate you fitting in my question. I'd like to ask about the receptor occupancy poster from late January that compared INGREZZA with Austedo. I'm curious about how you plan to use that information and what it could mean for your next-gen VMAT2 inhibitors. Thanks.
Yes — we're really encouraged by the data we presented, which is basically a head-to-head PET study of Austedo XR against INGREZZA. As we laid out in our recent press release, after a single dose we observed close to twice the target occupancy with INGREZZA compared with Austedo XR. And when we looked at steady state concentrations, we continued to see a clearly superior edge when it comes to VMAT2 target engagement. Our view is this reinforces the efficacy we observe with INGREZZA among patients in the community who have tardive dyskinesia, since we believe that the higher the VMAT2 target occupancy rate, the greater the efficacy when it comes to controlling tardive dyskinesia. On the second part of what you asked, we obviously have substantial experience in matching receptor occupancy to clinically efficacious doses. We're applying that relationship to our two VMAT2 follow-ons. In fact, we launched a phase II trial of our first follow-on in tardive dyskinesia very recently.
Great. Thank you.
Good afternoon. Thanks for taking our questions, and congratulations on a productive year. We just wanted to follow up on the question Paul raised about patient dynamics with CRENESSITY. I believe during your prepared remarks, you mentioned that patient demand might show seasonality, and I think investors were all debating whether there could have been an early launch bolus in patient initiations. We appreciate that you still have a lot to learn. What have you learned about those two factors in patient dynamics — one, an early launch bolus, and two, whether any seasonality exists as you go through the year? Thanks.
Yeah, thanks, Phil; this is Kyle. That's a fair question. It's worth remembering that the parallels Eric mentioned in his opening remarks hold up well and are accurate on every front. Regarding the initial year after launch, we've now completed our first Q1 through Q4. As we've seen with most orphan diseases and launches — whether INGREZZA or others — enrollment forms always experience ebbs and flows. Specifically at the start of a launch, it usually depends on how often people come into the office—that's when patients first learn about the chance for a new medicine—and on physicians spreading the word. So I believe it's premature to say whether a seasonal factor exists at all; you need a few quarters before you can reach those conclusions over several years. Reaching that degree of confidence with INGREZZA took us some time. At this point I think the sensible approach is to gather that data and then make a better-informed call regarding guidance, enrollment forms, and similar matters as the launch progresses further. You can be confident that we're hearing strong input from every stakeholder group—prescribers, physicians, and even payers. No one out there is suggesting we're doing anything other than heading toward a shift in the standard of care and reaching blockbuster status, just as we achieved with INGREZZA.
Hi folks, I appreciate you fielding my question, and congratulations from me too on such a productive year. My question concerns the expense side. It looks as though you anticipate somewhat of a modest rise in R&D costs this year compared with 2025. Could you elaborate a bit on what makes up that increase? What portion comes from earlier stage programs such as obesity? And once the two phase III trials read out, how fast might some of those costs come off in 2027? Thanks.
Yes, thanks for asking. The higher cost really follows from the phase III trials and from advancing them across a full year in 2026. For 2026, the obesity investment is in fact pretty minimal, though it is of course a very important program for us in terms of driving shareholder value creation, and we would expect some level of data in 2027. As for expense, when do expenses roll off? For the major phase III programs, we would anticipate those continuing through 2027, with a large portion dropping off in 2028.
Hey there, and thanks for the question. I'd like to revisit CRENESSITY briefly. As I recall, it was three or four years before any guidance was offered on INGREZZA — is that right? Which metrics did you have to gather before you felt comfortable issuing guidance? And do you have any sense of whether CRENESSITY will require a similar stretch of time before you feel confident enough to give sales guidance on it too? Thanks.
Hi, Tazeen. I might address your second question first. Reaching a point where we feel at ease providing guidance on CRENESSITY may happen faster than it did with INGREZZA, since this is a rare disease. INGREZZA is not a rare disease, though at that time it was rarely diagnosed; we essentially have one prescriber base in endocrinology as opposed to several specialties across various sites of care and so forth, and that made getting a handle on INGREZZA somewhat more difficult early on. As I noted in my prepared remarks, both are first-in-disease therapies and both are breakthrough medicines. As Kyle mentioned, we've now completed one cycle with CRENESSITY and classic CAH, and for us it has been a launch full of learning. A few things have turned out somewhat different from our expectations — though different in a good way. Coming into this launch, the adoption rate has exceeded what we anticipated, which is great. Reimbursement has clearly been favorable as well, and the persistency we've observed has pleased us greatly. Once patients begin treatment, they usually remain on it. As we gain additional experience within this community—the CAH community—and come to understand better how we can reach past that initial 10% of the population I mentioned, I believe we'll eventually reach a point where we feel more at ease offering specific guidance. We shouldn't mistake the absence of guidance for a lack of expectation regarding significant growth this year. All the signals we observe—consistent enrollment of new patients and patients remaining on therapy—indicate that strong growth will continue. It was simply a company decision not to provide a guide at this time.
Thank you, and good afternoon. Beyond the conversation about pricing for INGREZZA and Austedo — which I believe is now clearer to everyone — how are you viewing the volume effect on INGREZZA in the coming year, given that Austedo is turning into a negotiated product? And in a setting where pricing may be somewhat more competitive than we might have anticipated, how do you expect formularies to treat peer products? Thanks.
Sure, we have certainly been considering and getting ready for the 2027 formulary year and what it means for deutetrabenazine to have a negotiated MFP price. That said, our attention is very much on 2026 as we get set to move into the next phase. As Kyle mentioned in his prepared remarks, we are now in a position where we are carrying substantial momentum into 2026 when it comes to volume growth and new patient starts, with favorable coverage, particularly across the Medicare formularies, and we can build on all of that as we head into the 2027 formulary negotiations. So our strategy for 2027 feels solid to us. We think we will be able to keep formulary coverage in place to support continued growth. This market has grown at a double-digit rate for the past several years, which is quite remarkable, particularly for a category now entering year nine, year 10. So we feel good about 2026, we expect another very strong year for INGREZZA, and we feel good about our plan for sustaining that growth in 2027 and beyond.
Also — Kyle here — on 2026, our contracting is already locked in from what we pulled through during 2025, so we anticipate stability this year. There won't be mid-year additions the way there were in 2025. As we go into 2026, net revenue per prescription should stay about the same across the year. That means revenue growth ought to track volume growth well this year, which is what we expect — a strong year comparable to 2025. We're looking for solid double-digit volume growth and gains in market share as the year progresses.
Thank you. We had wanted to dig a little deeper into the—oh, hey, guys. Congratulations on everything you've accomplished, and thanks for fielding our question; what we're interested in is the NBI-568 trial and Alzheimer's psychosis, plus whatever lessons might carry over from the Adept-2 study of Cobenfy, particularly around how trial conduct is managed across study sites and any strategies you could deploy to reduce operational risks for that trial. Thank you.
Yeah, we're following how Cobenfy and AD psychosis are progressing rather closely; as a quick side note, though, psychiatry studies warrant particular attention, and we're lucky to have a highly experienced team that has run psychiatry studies successfully. So for both of our phase III studies, we devoted considerable time to carefully choosing sites and making sure the patients who enroll are genuine patients and not professional patients, who can inflate a placebo response. And indeed, when it comes to placebo mitigation, our strategy is multifold regarding study design, one-to-one randomization, and keeping study sites comparatively small. So, for instance, we have just 20 sites per phase III study for direlotide in our schizophrenia studies. And there's also a great deal of hands-on monitoring of sites and site investigators by our internal team. I think the BMS data have justified some caution about making sure we monitor these sites adequately, but we believe we're already in a pretty good position on that front.
Hello, Joyce Shao here on behalf of Anupam. We really appreciate you taking our question. Would you talk about what you've been hearing from KOLs regarding the two-year CRENESSITY data — particularly around how durable the benefit is — and how you expect that data to keep supporting and encouraging strong persistence among patients staying on treatment? Thank you.
Sure. We've received plenty of favorable feedback from clinicians who've been prescribing CRENESSITY, as you mentioned, for a while now. We shared that two-year data not long ago and, once again, it drew a very positive response. What matters a lot for these patients — and frequently for their parents — is demonstrating that androgens drop on a chronic basis and that doing so lets glucocorticoid doses come down to "physiological levels." That is an enormous thing for this population, who are basically burdened by the side effects of long-term glucocorticoid use. In our two-year dataset, we observed weight reductions among those who are obese, along with better insulin tolerance. Regarding androgen suppression, we additionally observed a slowing of bone age advancement — a major point for these patients and, again, their parents, since many of these individuals experience precocious puberty and fall short of their potential adult height. So we're genuinely pleased with that data and with the favorable effect on the community. Finally, I'd note the drug is in fact very well tolerated — highly important, especially in a pediatric population — with no surprises whatsoever even after gathering more than 35,000 patient weeks of exposure. Importantly, we do preserve the vasopressin-induced ACTH stimulus. I bring that up because adrenal insufficiency is a constant concern, especially when glucocorticoids are reduced. And we're quite happy with those adrenal insufficiency findings. In fact, there were no cases among the pediatric population, and the active-versus-placebo rate was equivalent in the adult population. So I hope that answers your question.
Kyle here. I’ll make just a couple of brief points on that. What I think really matters is this: when you look at safety and tolerability, in the open-label extension, 90% of subjects rolled over, and then 80% out to two years. That is simply an outstanding safety and tolerability profile. And with CH — though you could say this about a lot of disease states, and for CH even more than ever — efficacy may get your foot in the door, but safety and tolerability is what wins the day. Then the other piece is the efficacy we’re seeing at two years. It really captures the advantages of treating over the long term. You can genuinely alter how the disease progresses. The sooner you treat, the younger you are, and the longer you remain on treatment. So those are all good things to consider as we keep building this longer-term data.
Thanks a lot for the question. First, on the SG&A expense side: the rise in sales and marketing appears larger than what we saw a year ago. Could you help us understand whether that increase leans more toward CRENESSITY or toward INGREZZA? And I'd also like to understand your thinking on INGREZZA, since you're guiding to 10% growth, which is above last year's level. So do you expect volumes to keep expanding at last year's pace, or is it more that you're not anticipating any price decline this year? That's likely what's driving it. Thank you.
SG&A is mostly driven by the sales force expansion we discussed on the prior call — that's a big piece of it. We also have other ancillary initiatives around CRENESSITY and INGREZZA to ultimately drive sales. But for this coming year — or rather this year — we do expect double-digit growth, as we've said. That's partly offset by price, roughly negative 4%, reflecting the pricing and the contracting we entered into during the first half of last year. So you're looking at volume growth at the midpoint of our guidance range for INGREZZA in the mid-teens. So we feel really good about where the team is positioned; and of course, with the sales force expansion in place by the end of Q1, we'd expect more benefit to show in the second half of the year.
Great. Thank you.
Hi, thanks, everyone. My question concerns how many Tuesdays fall in each quarter. Actually, what I want to ask about is the sales force expansion for CRENESSITY onboarding in April. Do we need that in order to sustain this consistent influx of new patients for the product, or do you figure that at some point in the back half of the year, perhaps that expansion of the sales force will help the product inflect? Thanks.
Yeah, the way I'd frame it is this: we're putting money into growth. We feel quite bullish about what's possible with CRENESSITY and Classic CAH; and we settled on the size and structure of our sales force before launch without what I'd describe as the Monday morning quarterback chance to have additional data in hand. So clearly, we've been carrying out this expansion on a relative basis. It isn't a big number of FTEs that we're bringing into the CRENESSITY team, but we do believe it will let us accomplish a couple of things. First, it lets us go deeper within the current prescriber base. And in my prepared remarks, I mentioned how we now have more than 1,000 doctors who have prescribed CRENESSITY, and yet 2/3 of them have only treated one patient thus far. So we know those practices hold more patients. Because territory sizes are very large, this will let us get in and follow up with current prescribers somewhat more often. Second, we also recognize that certain patients out there haven't been reachable through the sales team as it stands. So we can go deeper into endocrinology, and we recognize that some patients aren't cared for by an endocrinologist. They might be seeing an internal medicine or a family medicine physician or even an OB/GYN. So we now have the chance to explore that somewhat with the larger sales team. The last thing I'll mention is that we're enthusiastic about the reputation we've built within the endocrinology community; we're able to draw some truly high potential people, and I think people with great track records, onto the team. We've in fact finished expanding that group; they're in training now, and they'll be ready to deploy into the new organizational structure at the start of Q2. So it's full steam ahead with the expansion and certainly we're very excited about the extra bandwidth we'll have created as we execute against it.
Miles is going to host a webinar on the calendar and how it shapes the remainder of the year — just joking. But I did want to revisit something Phil asked about, regarding seasonality for CRENESSITY, and I think Kyle and Eric handled that well when they noted we don't yet have sufficient experience on the demand side for CRENESSITY. I had meant to bring up that Q1 carries a gross-to-net effect. That effect is roughly 5%, and it ties to the commercial copay reset. So that's one item I wanted to flag as you build out your models and expectations for CRENESSITY in Q1. Please factor that in. Thank you.
Hello, wonderful. Thanks so much. And nice work on everything that's been achieved. I was hoping to explore a little further that 10% share in CAH. Is it correct that this is completely endos? Are you noticing any initial share coming from certain other categories you brought up, like PCPs and OB/GYN? Also I'm curious how far you can currently leverage some of the AI database inferencing to help figure out which PCPs and OB/GYNs might be the strongest candidates for CRENESSITY.
Yeah. Alright, let me clarify something—in my prepared comments, I mentioned that we figure we've gotten roughly 10% of the prevalent CAH population onto treatment. Stepping back for a moment: in the U.S., we estimate there are about 20,000 individuals with Classic CAH. And clearly, reaching around 10% of them and getting them on therapy in year one is a really significant milestone for us. Nearly all of those new patient starts have come from within endocrinology. We realize that to keep growing CRENESSITY’s use and reach a wider portion of that patient population, we’ll need to connect with patients outside the prescriber base we’ve already accessed. You brought up patient finding. I touched on that briefly in my prepared remarks; we’re therefore using various technology platforms and datasets that help us pinpoint where patients appear similar—at least in the data—to those we’ve already started on treatment, and then let our field sales organization follow up and verify whether those patients are present at this or that practice. Feeding those insights back into the system sharpens its intelligence, which in turn lets us refine how we target. Now, Classic CAH is uncommon, and no dedicated diagnostic code exists for it. That means sustaining our expansion—and delivering the consistent growth we anticipate—requires us to harness both technology and our people.
Thank you. Perhaps I could pose a second CRENESSITY question, though framed differently. When you consider how to drive deeper penetration, is there any resistance coming from endocrinologists? Or, to put it another way, what obstacles to broader adoption are you encountering? And separately, regarding the competitor now in development — the ACTH antagonist — do you get the sense that physicians are holding off until that drug becomes available so they can place patients on that approach rather than CRENESSITY? If you could address that dynamic too, that would be great. Thank you.
Sure, let me take the second question first. The answer is no. I don't believe community endocrinologists, by and large, know about an investigational drug, nor are they warehousing patients or delaying their care for something that may or may not reach the market several years from now. As for the biggest obstacle, I'd point to a lack of knowledge. Here's why I say that: yes, certain endocrinologists are quite familiar with these patients and skilled at managing them, but the great majority of community endocrinologists have minimal experience with Classic CAH. When CAH patients show up in a doctor's practice, there might only be one or two of them. A big part of what we do on the education side — I touched on this in my prepared remarks — involves keeping the focus on teaching about Classic CAH, about how high-dose glucocorticoid treatments fall short, about what happens when patients get too much or too little treatment, and then tying all of that to the clinical profile that has come forward for CRENESSITY, especially the very strong safety and tolerability data we've observed in both the trials and real-world experience. So the goal is essentially to help physicians move beyond what I'd describe as the pre-CRENESSITY belief that their patients are already being treated with these steroids. They believe things are going well, yet upon closer inspection they find substantial comorbidity and complication burdens arising either from the disease itself or from their GCs. As our education efforts keep expanding, we're definitely observing that physicians recognize CRENESSITY represents an entirely novel approach to managing CAH. It's a paradigm shift. Adoption has, I think, confirmed that. Another point I'd make is that we've collaborated very closely with the CARES Foundation, a patient advocacy group. As a partner in educating its membership, they've been wonderful. As we approached this launch, it was clear to us that many CAH patients and their families lacked a complete picture of what uncontrolled androgens, excess glucocorticoid exposure, or both can bring about. That's why our education work keeps reaching not only HCPs but the patient community as well. In my view, both groups stand to gain from it.
Hey, team. Appreciate the question. Luke here, filling in for Brian. So regarding CRENESSITY and that remaining roughly 90% of prevalent patients who aren't treated, could you remind us how much of that share is handled by an endocrinologist versus primary care or other settings?
Yeah, I think that's something we're picking up on. So it's hard to tell you precisely what share of patients are looked after by an endo as opposed to a PCP; and one thing we've noticed, at least among the group of patients who've already begun CRENESSITY, is that a number of them seem to be managed jointly by endocrinologists and primary care. And it could be that they visit their endocrinologist once a year, yet they might be seeing their primary care physician more often. And the question becomes who's handling their CAH and refilling their prescriptions, and so forth. So going forward, pulling that apart from the data, I think, is really important. I think that, as I said earlier, being able to spot those primary care or OB practices that seem to have multiple CAH patients and having our sales team go in there and follow up, that builds the mechanism or the feedback loop that lets us understand where these patients are and the best way to educate, motivate, and activate these patients.
Matt, a fast clarification if I may. You mentioned a -4% price outlook for 2026. Is that figure being compared with the 5,500 that I think was the full-year 2025 guidance given earlier? Then I have one additional follow-up about the ACTH antagonists discussion and how you expect that drug would ultimately be used, assuming it ever reaches the market with everyone, hopefully, on CRENESSITY by that time. Would it serve as an add-on? Do you see it as a competing product, or what's your view of it at that stage? Thanks.
We haven't shared the net price figure for 2025, but the 4% can be viewed as a year-on-year figure, weighted more heavily toward the first half of this year given when our contracting took place. The key point, though — and Kyle brought this up before — is that as we exit 2025, our net revenue per script will stay very similar across all of 2026. So we did capture some price during 2025, but we expect considerable stability when it comes to net price, and even more importantly, on the access side, which should keep letting us grow this market.
Now, Marc, regarding your question about competitors, I've picked up quite a bit during my first full year in the CEO role, and one lesson is how to discuss competition. With CRENESSITY, we're actually dealing with two separate programs, two separate medicines, each at a separate stage. CRENESSITY is an approved medicine, it launched very well, and we enjoy a multi-year lead. My view is that we have a medicine that is transforming the standard of care in terms of efficacy, safety, tolerability, and formulations, and we keep generating substantial data as time goes on. That puts us, I believe, in a very strong position. And I think that all of you listening on the phone — I've certainly been doing that here, examining orphan drug launches — it's genuinely difficult for me to identify any medicine that matches what CRENESSITY offers and gets displaced at all by a future medicine. I'm truly enthusiastic about what we have with CRENESSITY. For us, it's positive on two fronts. We have an excellent medicine and an excellent team out there accomplishing excellent things with prescribers and patients. Our focus will be on growing this brand into a great medicine for patients and for the company.
Hello, Stevie here, filling in for Akash. Thanks for taking our question. I'd also like to ask about CRENESSITY, though my focus is more on the pipeline; we noticed a phase II study is being started for patients under four years old, a group we understand isn't on the label right now. Could you discuss the significance of that study and when an update should be expected? And might this represent a growth opportunity if and when it reaches the market for that population? Thank you.
Yes; so as was noted, we are launching 2032 shortly, a pediatric trial. Those enrolled are under four years of age, with the youngest at three months. The goal is to broaden our label, which at present covers four years and older. So once more, this opportunity has us excited. Data from that study should be available next year.
Good afternoon, and thank you for taking our questions. Here's a bigger-picture one. It appears you recently divested your rare commercial business in the U.K. and Europe. What are the implications for your plans to develop crinecerfont in the U.K. and across the rest of Europe? And does that move signal that Neurocrine will stay focused solely on the U.S.? Also, how significant a role did the possible enforcement of Most Favored Nations pricing play in that decision?
Yeah, Kyle here. Thanks for the question. Regarding the EU business, the programs we had underway there didn't really fit well with what our own portfolio looks like today. So we found a solid home for those programs with a new team over there. As for our own priorities, clearly we're concentrated on the U.S. market at present, making sure we deliver a strong launch here with CRENESSITY. Things are going well so far on that front. We intend to keep our focus there while exploring ways we might eventually bring CRENESSITY and other future medicines to Europe. At this moment, we aren't really weighing the considerations and factors tied to Most Favored Nation as such; our attention is mostly on the U.S. market. That said, it's an evolving area. Before we make any definitive moves outside the U.S., we'll want clarity on where things are heading from a policy perspective here.
Hello, Kyle and everyone. I trust you're all doing fine. I appreciate you taking my question. My question concerns the pipeline and 890. Looking again at the data you presented recently for INGREZZA and that 80% receptor occupancy figure, that appears to be quite a demanding bar. Do you believe 890 can surpass it, or is the real story with 890 simply growing the patient population via its long-acting characteristics?
That's a very good question, since as you noted, with INGREZZA we're in fact performing very strongly when it comes to receptor occupancy; thus for 890, our expectation is receptor occupancy at least equal to that. Yet as you suggest, the promise of long-acting injectable formulations stems from lower clearance as well as lower aqueous solubility. So this is a molecule genuinely built to be oral yet given at fairly infrequent intervals; and we believe that might reach patients who aren't faring well or aren't complying well with their existing therapy.
Yeah, to build on that, we’ve definitely examined that possibility with INGREZZA over time. And it isn’t a particularly well-suited molecule for that, nor are the other follow-on molecules we’ve had over time. So we’re quite excited. But with 890 and 675, those represent the next-generation VMAT2 inhibitors. And it’s taken us a while to get a molecule that actually has a profile we believe is competitive or, if not, better than INGREZZA. So we’re excited about getting this phase II study up and running and looking to have data sometime toward the end of next year.
Hello, everyone, and good afternoon. I really appreciate the question. So, I realize we've discussed at length the broader obstacles around prescribing CRENESSITY, and we've noted on a few occasions that two-thirds of your prescribers have written just one prescription. I suppose I'm simply attempting to grasp what specifically is causing that pattern. Typically, how many CAH patients are these physicians managing? And what feedback are you receiving about the barriers or hesitations that exist when it comes to broadening adoption more widely across these particular prescribers' patient bases at this point? Thank you.
Sure — I think the situation will vary from one physician to another. Broadly, though, the two main things shaping how quickly adoption moves, particularly among those who have written one prescription, are really the patient flow coming into the practice. As I said earlier, many of these community endocrinologists treating adult patients may see a given patient only once a year. So that's one factor; and the second is — and this isn't specific to CRENESSITY — many of these physicians, when they start someone on therapy, want to observe how that patient does and gain some clinical experience. Typically, a few months into treatment is when they would begin the GC tapering. From what I hear anecdotally, a lot of them are proceeding cautiously, simply lowering the GC doses gradually. So it isn't a forced down titration. Together, I think those two factors get at what may be holding some of these doctors back from putting their second or third patient on treatment. But as I said earlier, most community adult endocrinologists, if they have classic CAH in their practice, have only a few patients. So this is a market with a small number of what I'd call KOLs or experts, and then a large number out in the community who have very few patients; so it's an inch deep and a mile wide, so to speak; but for us to truly optimize this opportunity, we have to reach and educate everyone; and that's what we're doing. Obviously, we're very pleased with the first year. We expect a lot of success in 2026 and beyond.
Thank you, Clay. I appreciate everyone taking the time to be with us today and for the productive conversation. On this call, we provided updates regarding our commercial results and development programs, along with the business outlook. Let me state this plainly. As we look toward 2026, disciplined execution stays our priority, and that involves a couple of things: growing revenue and diversifying through INGREZZA and CRENESSITY, moving the pipeline forward while creating meaningful long-term value for patients and shareholders; we have considerable momentum building this year ahead of a data-rich 2027. That is really only the beginning. The pipeline's structure will produce a steady stream of data beginning in 2027 and continuing in the years beyond. So, to wrap up, feel free to contact us about anything we covered today; we look forward to keeping the conversation going and to meeting with many of you as we move through the year. Thanks once more, and speak with you soon.
Thanks — that takes us to the finish of today's meeting. We're grateful for the time you've given and for taking part. You're welcome to disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Neurocrine Biosciences, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Neurocrine Biosciences, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.